# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-21-013102
Filing Date
2021-04-16
Accepted
2021-04-16 16:28:20
Documents
5
Period of Report
2021-05-28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | nc10020263x1_def14a.htm | DEF 14A | 1495657
2 |  | nc10020263x1_linechart01.jpg | GRAPHIC | 226857
3 |  | nc10020263x1_pc1.jpg | GRAPHIC | 645034
4 |  | nc10020263x1_pc2.jpg | GRAPHIC | 809892
5 |  | sig_kellymacdonald.jpg | GRAPHIC | 13057
| Complete submission text file | 0001140361-21-013102.txt |  | 3829840

Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34207 | Film No.: 21831844
SIC: 2834 Pharmaceutical Preparations